Literature DB >> 10608011

Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy.

.   

Abstract

The use of antithrombotic therapy has taken on central importance in the field of cardiovascular disease. Currently, anticoagulants and antiplatelet drugs are central to the treatment and the primary and secondary prevention of coronary artery disease. New insights into the "revised" coagulation cascade have highlighted new targets for intervention. In addition, the interactions between the coagulation system and platelets demonstrate ways that anticoagulants may affect platelet function and how antiplatelet agents may have anticoagulant effects. This overview will describe the present understanding of primary and secondary hemostasis, and current and future therapeutic approaches to modify these systems for therapeutic effects in cardiovascular medicine.

Entities:  

Year:  1995        PMID: 10608011     DOI: 10.1007/bf01064376

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  75 in total

1.  Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.

Authors:  J M Maraganore; P Bourdon; J Jablonski; K L Ramachandran; J W Fenton
Journal:  Biochemistry       Date:  1990-07-31       Impact factor: 3.162

2.  A Brief Account of a Disease in Cattle Simulating Hemorrhagic Septicaemia due to Feeding Sweet Clover.

Authors:  F W Schofield
Journal:  Can Vet J       Date:  1984-12       Impact factor: 1.008

3.  Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.

Authors:  E Skrzypczak-Jankun; V E Carperos; K G Ravichandran; A Tulinsky; M Westbrook; J M Maraganore
Journal:  J Mol Biol       Date:  1991-10-20       Impact factor: 5.469

4.  Mechanism of action and monitoring of anticoagulants.

Authors:  J Hirsh
Journal:  Semin Thromb Hemost       Date:  1986-01       Impact factor: 4.180

Review 5.  Aspirin as an antiplatelet drug.

Authors:  C Patrono
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

6.  A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.

Authors:  A G Turpie; M N Levine; J Hirsh; C J Carter; R M Jay; P J Powers; M Andrew; R D Hull; M Gent
Journal:  N Engl J Med       Date:  1986-10-09       Impact factor: 91.245

7.  Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins.

Authors:  A R Hubbard; C A Jennings
Journal:  Thromb Res       Date:  1987-05-15       Impact factor: 3.944

8.  Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.

Authors:  R M Lidón; P Théroux; M Juneau; B Adelman; J Maraganore
Journal:  Circulation       Date:  1993-10       Impact factor: 29.690

9.  Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex.

Authors:  J M Teitel; K A Bauer; H K Lau; R D Rosenberg
Journal:  Blood       Date:  1982-05       Impact factor: 22.113

10.  The structure of a complex of recombinant hirudin and human alpha-thrombin.

Authors:  T J Rydel; K G Ravichandran; A Tulinsky; W Bode; R Huber; C Roitsch; J W Fenton
Journal:  Science       Date:  1990-07-20       Impact factor: 47.728

View more
  1 in total

1.  Adaptation of a photochemical method to initiate recurrent platelet-mediated thrombosis in small animals.

Authors:  Karin Przyklenk; Peter Whittaker
Journal:  Lasers Med Sci       Date:  2007-03       Impact factor: 3.161

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.